BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- inVentiv
Health Clinical, a leading global supplier of drug development
services, announced today that it has been selected for an
osteoarthritis Investigational New Drug Application (IND) by the
innovative regenerative medicine biotechnology company IntelliCell
BioSciences, Inc., (OTCQB:SVFC). IntelliCell will be studying the
use of adult autologous vascular cells from blood vessels in
adipose tissue to treat osteoarthritis of the knee.
The principal investigator is Dr. James
Andrews, an orthopedic surgeon known internationally for his
scientific and clinical research into knee, shoulder and elbow
injuries. Dr. Andrews is a founding member of the American
Sports Medicine Institute, author of numerous scientific articles
and books and founding partner and medical director at the Andrews
Institute in Gulf Breeze,
Florida.
inVentiv Clinical will work with Dr. Andrews to develop
investigational clinical study protocols and will serve as the
Clinical Research Organization (CRO) on trials conducted at the
Pensacola Center of the Andrews Institute.
IntelliCell's technology for isolating stromal vascular fraction
cells from the vasculature of adipose tissue has been used to treat
more than 60 knees. IntelliCell's Chief Executive Officer,
Dr. Steven Victor, said this is what
we believe will be the first of several clinical trials for the
biotech company studying the use of its technology in treating a
variety of diseases and conditions.
"inVentiv Clinical has extensive therapeutic experience in
general pain and osteoarthritis programs and a focus on partnering
with innovative bioscience companies," said Raymond Hill, President of inVentiv Health
Clinical. "We are looking forward to our work with Dr.
Andrews and contributing to advances in the treatment of
osteoarthritis in knees."
inVentiv Health Clinical offers clients a full range of clinical
research services supported by a global infrastructure,
therapeutic expertise, and unmatched commitment to quality. For
pharmaceutical, biotechnology, generic drug, and medical device
companies, inVentiv conducts Phase I-III clinical trials, Phase IV
late stage post-approval programs, as well as offering staffing,
bioanalytical and regulatory services.
IntelliCell's IND study will focus on proving the company's
patented technology of Ultrasonic Cavitation as a method of
producing stromal vascular fraction cells as a new approach and
improvement on current treatment which in the worst cases can
involve surgery.
About 75% of people over 70 years of age show changes consistent
with osteoarthritis and symptoms such as pain, joint stiffness and
joint deformities. Osteoarthritis affects more than 25 million
people in the United States
alone.
Regenerative medicine is the process of replacing or
regenerating human cells, tissues or organs to restore or establish
normal function by replacing damaged tissue and/or by stimulating
the body's own repair mechanisms to heal previously irreparable
tissues or organs.
IntelliCell is planning an in-human clinical trial in late 2014
to study if the IntelliCell vascular fraction cells may demonstrate
measurable benefits for patients suffering from this debilitating
condition.
About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services
company purpose built for the new healthcare environment. Creating
a new model for the new marketplace, inVentiv offers convergent
services that accelerate the performance of companies developing
and commercializing drugs to improve patient outcomes worldwide. In
40 countries around the world, inVentiv's 12,000 employees work
with more than 550 pharmaceutical, biotech and device companies, as
well as companies that see health as a central part of their
mission. inVentiv Health, Inc. is privately owned by inVentiv Group
Holdings, Inc., an organization sponsored by affiliates of Thomas
H. Lee Partners, L.P., Liberty Lane Partners and members of the
inVentiv management team. inVentiv Health helps clients transform
promising ideas into commercial reality. For more information,
visit www.inVentivHealth.com.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell BioSciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
universities, and international business entities.
Contact:
Danielle DeForge
inVentiv Health, Inc.
+1 781 425 4624
danielle.deforge@inventivhealth.com
SOURCE inVentiv Health Clinical